Clinical trials: Steroid Refractory
Asthma
Small Particle Steroids in Refractory Asthma
The purpose of this study is to determine whether an inhaled steroid with a small particle size can be an additional treatment option in patients with refractory eosinophilic asthma.
- Trial name
- SPIRA (NCT01171365)
- Testing
- Ciclesonide
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Nottingham
Graft vs Host Disease
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
To determine if subjects with steroid refractory cGVHD can tolerate imatinib mesylate and whether their cGVHD responds to imatinib mesylate.
- Trial name
- NCT00760981
- Testing
- Imatinib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- David Miklos
Graft vs Host Disease
Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
To study the effectiveness of an immunosuppressive drug sirolimus, in the treatment of chronic graft versus host disease in combination with prednisone.
- Trial name
- NCT00388362
- Testing
- Sirolimus, Prednisone
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Stanford University
Graft Versus Host Disease
Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients
In this study the investigators evaluate the outcomes of six steroid-refractory GVHD patients with gastrointestinal signs of GVHD that were treated with teduglutide.
- Trial name
- NCT04290429
- Testing
- Teduglutide
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- University of Freiburg
Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF)
Managed Access Programs for INC424, Ruxolitinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib
- Conditions
- Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF), Severe/Very Severe COVID-19 Illness
- Trial name
- NCT04745637
- Testing
- Ruxolitinib
- Sponsor
- Novartis Pharmaceuticals
Acute Graft Versus Host Disease in Intestine
FMT for Pediatric SR-aGVHD
This is a pilot, prospective, non-profit, multicenter, uncontrolled, open-label study to evaluate the safety and feasibility of FMT in patients aged between 3 months and 25 years suffering from acute intestinal GVHD resistant to…
- Trial name
- NCT07602751
- Testing
- Fecal Microbial Transplantation
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Bullous Pemphigoid
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment
To evaluate the safety and efficacy of QGE031 versus placebo in patients with bullous pemphigoid. Efficacy will be assessed as a reduction of disease activity.
- Trial name
- NCT01688882
- Testing
- QGE031
- Where
- 9 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Refractory Lumbar Disc Prolapse
Caudal Epidural Steroid Injection Ultrasound Guided in LDP
Patients with LDP with unilateral radiculopathy diagnosed by routine clinical examination and MRI, in whom conservative treatment (medical treatment and physiotherapy) failed for more than 6 weeks and refuse surgery or were unfit…
- Trial name
- NCT03933150
- Testing
- ultrasound guided caudal epidural injection
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Mansoura University
Fecal Microbiota Transplantation
Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer
Patients who have a gastrointestinal acute Graft versus host disease (GVHD) received a first-line standard treatment of corticosteroids. For patients who do not respond or progress after an initial response have a high mortality.
- Trial name
- HERACLES (NCT03359980)
- Testing
- fecal microbiota transfer
- Where
- 16 sites in France, Italy and 1 more
- Volunteers
- 24 people
- Sponsor
- MaaT Pharma
Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific
Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
RATIONALE: Thalidomide may interfere with the body's ability to recognize transplanted bone marrow cells as foreign and may help treat patients with graft-versus-host disease.
- Conditions
- Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003894
- Testing
- thalidomide
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Roswell Park Cancer Institute
Steroid Refractory GVHD
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05663827
- Testing
- Ruxolitinib
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Yi-Lun Wang
Graft Versus Host Disease
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
- Trial name
- NCT02195869
- Testing
- Ibrutinib
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pharmacyclics LLC.
Chronic Graft-versus-host Disease
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Chronic GVHD is a medical condition that may occur after a bone marrow, stem cell or cord blood transplant. The donor's immune system may recognize the your body (the host) as foreign and attempt to 'reject' it.
- Trial name
- NCT01366092
- Testing
- Interleukin-2
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic GVHD After HCT for Cancer or Immune Disease
Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD
Phase II multicenter, Canadian only study - open to 25 subjects. Study open to subjects with steroid-refractory or dependent chronic graft vs host disease. Series of 6 aphereses and 28 re-infusions over 24 weeks.
- Trial name
- CARE (NCT02519816)
- Testing
- Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- daphne brockington
Chronic Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
This phase I trial studies the side effects of leflunomide in treating patients with steroid dependent chronic graft versus host disease (cGVHD). cGVHD is a common complication of bone marrow transplant.
- Trial name
- NCT04212416
- Testing
- Leflunomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Chronic Graft Versus Host Disease
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment.
- Trial name
- NCT02337517
- Testing
- Laboratory Biomarker Analysis, Vismodegib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Steroid-Refractory Chronic GVHD
Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Chronic GVHD is the most common late complication following allogeneic stem cell transplantation. It has features resembling autoimmune disorders such as scleroderma, primary biliary cirrhosis, bronchiolitis obliterans, chronic…
- Trial name
- NCT00472225
- Testing
- Rituximab
- Where
- 9 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- The Korean Society of Hematopoietic Stem Cell Transplantation
Immune Thrombocytopenia
The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and ATRA in patients with steroid-resistant/relapsed ITP.
- Trial name
- NCT03304288
- Testing
- Rituximab, All-trans retinoic acid
- Where
- 4 sites in China
- Volunteers
- 168 people
- Sponsor
- Peking University People's Hospital
Chronic Graft Versus Host Disease
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD
Chronic Graft versus Host Disease (cGvHD) has been identified as the leading cause of late non-relapse mortality in Hemopoietic Stem Cell Transplant (HSCT) survivors.
- Trial name
- Nilo-cGVHD (NCT01810718)
- Testing
- nilotinib
- Where
- 12 sites in Israel, Italy
- Volunteers
- 22 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Chronic Graft Versus Host Disease cGVHD
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Phase 1b: To evaluate the safety and tolerability of multiple ascending doses of efavaleukin alfa in subjects with steroid refractory chronic graft versus host disease (cGVHD).
- Trial name
- NCT03422627
- Testing
- Efavaleukin Alfa
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 32 people
- Sponsor
- Amgen